137 results about "Antihypertensive medicines" patented technology

The present invention relates to the preparation of Timisatan as one active component for antihypertensive medicine. The carboxylic ester derivative is first obtained through the nucleophilic substitution reaction between some intermediate and 4'-bromomethyl biphenyly-2-carboxylic ester, and then hydrolyzed to eliminnate protection radical and to obtain the destination product. In the technological process of the present invention, methyl radical and ethyl radical are used as protecting radical, and this facilitates and stabilizes the preparation of 4'-bromomethyl biphenylyl-2-methyl carboxylic ester and 4'-bromomethyl biphenylyl-2-ethyl carboxylic ester, and results in easy to control reaction with the intermediate, less impurity, easy elimination of protecting radical and high product yield and quality.

A depressor peptide with higher suppression activity to angiotensin-converting enzyme (ACE) and having 6 amino acids is prepared from the protein of Chinese shrimp through enzymolyzing, separation and purifying. Its short peptide with 12 sequences is chemically synthesized. It can be used to prepare antihypertensive medicine.

A composite medicine for improving the curative effect of the antihypertensive medicine containing Ca channel retardant and preventing the complications such as eyeground hemorrhage, angina pectoris, myocardial infarction, cerebral apoplexy, heart failure and kidney failure is composed of Ca channel vetardant or its precursor or its active metabolite or its salt, one or more of vitamins in B family and the pharmacologically acceptable carrier.

The invention provides a valsartan compound and a new manufacturing method thereof. In the invention, through specially designed methods for acid and alkali conversion and absorption by macroporous absorption resin, the aim of refining and purifying can be fulfilled; and thus, the high-purity valsartan compound is obtained, the product quality of the preparation is improved, the toxic and side effects are reduced, and the clinic medicine safety of the valsartan in the preparation of antihypertensive medicines is guaranteed.

The invention discloses polypeptide of Phascolosoma esculenta which is a polypeptide segment prepared through hydrolysis of extracted protein of the Phascolosoma esculenta. The protein of the Phascolosoma esculenta comprises water-soluble protein, waterinsoluble protein and a mixture thereof. The hydrolysis method comprises protease hydrolysis, acid hydrolysis and alkali hydrolysis. The polypeptide of the Phascolosoma esculenta can be used for inhibiting angiotensin converting enzyme (ACE), so the polypeptide can be used for preparing antihypertensive medicines, and a new way for effectively utilizing the Phascolosoma esculenta is opened up.

The invention relates to antihypertensive nutritional health-care rice and a making method thereof. The antihypertensive nutritional health-care rice comprises rice, red pearl rice, shelled buckwheat, shelled oatmeal, small red bean, fructus lycii, hawthorn and carrot dices. The making method of the antihypertensive nutritional health-care rice includes the steps of soaking and drying the materials, and adding water to boil to obtain the antihypertensive nutritional health-care rice. The antihypertensive nutritional health-care rice is reasonable in proportion, nutritional, scientific, and rich in nutrients necessary to human bodies. The rice can be boiled with a ceramic pot into boiled rice, which is fragrant and attractive in color, has the effects of heat clearing, detoxication, blood lipid lowering, spleen tonifying, stomach invigorating, liver nourishing and blood pressure lowering, and has dietary and health-care functions.

Methods and therapeutic combinations are provided for lowering blood pressure in a subject exhibiting resistance to a baseline antihypertensive therapy with one or more drugs, or a subject having diabetes and/or chronic kidney disease. A method of the invention comprises administering, in some embodiments adjunctively with a modified baseline therapy, a compound of formula (I) as defined herein. A therapeutic combination of the invention comprises a compound of formula (I); at least one diuretic; and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers; wherein the at least one diuretic and/or the at least one antihypertensive drug are present at substantially less than a full dose.

The present invention provides a an angiotensin receptor antagonist and creatine phosphate sodium complex and uses thereof, wherein the complex comprises an angiotensin receptor antagonist and creatine phosphate sodium, a molar ratio of the angiotensin receptor antagonist to the creatine phosphate sodium is 1:1-2, and the angiotensin receptor antagonist is selected from valsartan, losartan, irbesartan, telmisartan, eprosartan, candesartan, olmesartan, saprisartan, tasosartan, and elisartan. According to the present invention, the complex is formed by compounding the angiotensin receptor antagonist and the creatine phosphate sodium, and provides the unexpected double effect and the synergistic effect for treatment of heart failure and high blood pressure, the cocrystallization salt hydrate formed by linking the hydrogen bond has the stable characteristic, the pharmacokinetic property is significantly provided, and the positive application prospects are provided in the fields of anti-high blood pressure treatment and anti-heart failure treatment.

The invention relates to a pharmaceutical composition containing azilsartan. The pharmaceutical composition particularly comprises azilsartan and at least one other antihypertensive medicine. The collaborative antihypertensive effect can be effectively played. The pharmaceutical composition for lowering blood pressure, which has a good antihypertensive effect, stable pressure reduction, and good tolerance, is provided.

Disclosed is a novel fused bicyclic compound [I] shown below, which has affinity for a mineralcorticoid receptor (MR) and is useful as an anti-hypertensive agent or the like. Specifically disclosed is a compound represented by the formula [I] or a pharmacologically acceptable salt thereof. [I] wherein the ring A represents a benzene ring which is fused with the adjacent heterocyclic 6-membered ring and has a substituent R1, and which may have a substituent other than R1; R1 represents an alkylsulfonylamino group or the like; R2 and R3 (a) independently represent a hydrogen, an alkyl or a substituted or unsubstituted aryl, (b) together form an oxo, or (c) together with the adjacent carbon atom, form a cycloalkyl; X represents =N-, =C(R4)- or -CH(R4)-; R4 represents (a) a hydrogen, (b) a cyano, (c) a halogen, (d) an alkyl, (e) an alkenyl, (f) a cycloalkyl, (g) an alkanoyl, (h) a carbamoyl or (i) a cycloalkenyl; Ar represents a substituted or unsubstituted aromatic cyclic group; and a dotted line means the presence or absence of a double bond.

An antihypertensive drug cilazapril intermediate is the compound of the structural formula 1, which is obtained by the steps of alkalising the compound of structural formula 2 to remove L-tartaric acid and obtaining the compound of structural formula 3, subjecting the compound of structural formula 3 and the compound of structural formula 4 to a reaction to obtain a single SS-configuration compound 1 of structural formula 1. The compound of structural formula 1 in the invention is cyclized to obtain the compound of structural formula 8. The compound of structural formula 8 is processed by reduction through borane, protective group removal and suprafacial chain condensation, and is processed by tertiary butyl protective group removal under the action of hydrochloric acid gas so as to obtainthe antihypertensive drug cilazapril 13. The invention uses front split, obtains a single SS-configuration new compound of structural formula 1, avoids column-passing spit in subsequent procedures, s implifies synthesis technology, decreases cost, and reduces three wastes. Thus, the invention is more suitable for commercial production.

The present invention relates to sustained release solid pharmaceutical composition comprising antihypertensives, in particular, Metoprolol succinate or pharmaceutically acceptable derivatives thereof and a process for preparing such a formulation. The present invention is a composition comprising Metoprolol succinate or its pharmaceutically acceptable derivatives thereof and the composition releases the drug over 24 hours. The composition further comprises hydrophilic polymer matrix based tablets. The present invention describes a sustained release tablet comprising sustained release matrix comprising of gelling agents comprising at least one hydrophilic polymer with one or more gum and gum derivatives.

The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-4 (DPP-4) inhibitor and an anti-hypertensive agent selected from the group consisting of an angiotensin II receptor antag-onist and an angiotensin converting enzyme inhibitor, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes-related disorders, hypertension, and hypertension-related disorders.

The invention discloses a compound oral preparation and a preparation method thereof. The compound oral preparation is used for treatment of high blood pressure and has significant effect. The preparation includes three anti-hypertensive drugs hydrochlorothiazide, amlodipine besylate, valsartan and pharmaceutical excipients. The three components all belong to hydrophobic drugs, so that the dissolution rate is one of the key indicators measuring the intrinsic quality of the preparation. A specific ratio of the raw materials to the excipients is adopted by the invention, especially a polyoxyethylene-polyoxypropylene copolymer is used, for instance poloxamer serves as a solubilizing agent, so that compared with the anti-hypertensive compound preparation EXFORGE HCT produced by American Novartis pharmaceutical company, the compound preparation has good similarity in terms of dissolution behavior. According to the invention, wet granulation or dry granulation is employed to effectively solve the problems of low bulk density, poor liquidity, strong moisture absorption, and sticking and picking of Valsartan. The preparation method of the compound preparation is simple and practical, and the product has stable quality, and good dissolution rate and content uniformity of each effective component, thus being suitable for large-scale industrial production.

The invention relates to a synthesis method for preparing an antihypertensive medicine having a benzofuroxan ring. In the method, 4-methylbenzofuroxan is used as a raw material, the 2,1,3-benzoxadiazole-4-aldehyde serving as an important intermediate is prepared by bromination and oxidation reactions, and the 2,1,3-benzoxadiazole-4-aldehyde and acetoacetic ester undergo a Hantzsch reaction to form the target compound. Compared with other processes, the method has the characteristics of mild reaction conditions, simple and efficient operation, high yield and the like and has a certain industrial production prospect.

Modified or extended release formulations containing propanolol compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved propanolol formulations such as INDERAL LA®.

The invention discloses an antihypertensive royal jelly composition. The antihypertensive royal jelly composition is prepared from the following raw materials in parts by weight: 60 to 80 parts of royal jelly, 35 to 48 parts of honey, 5 to 10 parts of bee pollen, 20 to 35 parts of emulsifiers, 3 to 12 parts of glycerinum, 10 to 18 parts of tea polyphenol, 5 to 8 parts of lycopene, 5 to 10 parts of rock candies, 1.2 to 3.5 parts of lucid ganoderma, 5 to 8 parts of radix puerariae, 2.3 to 5.8 parts of harlequin glorybower leaves, 1 to 8 parts of uncaria rhynchophylla, 1 to 9 parts of prunella vulgaris, 10 to 20 parts of wild chrysanthemum flowers, 5 to 10 parts of semen cassia, 3 to 9 parts of cattail pollen and 2 to 7 parts of rhizoma alismatis. The antihypertensive royal jelly composition is reasonable in composition proportion, complete and rich in nutrients, high in content of active ingredients, free from additives by adopting the pure natural traditional Chinese medicine formula, non-toxic, free from side effect on the human body, capable of being eaten for a long time, and remarkable in antihypertensive effect.

The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds of formulas (I), (IIa), (IIIb) in hydrophilic or lipophilic form, which are useful as angiotensin II AT1 receptor antagonists with sympathetic suppressant properties. In particular, the invention provides pharmaceutical compositions containing the pharmacophoric groups of Losartan and Clonidine as well compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases through Renin Angiotensin System (RAS) and Sympathetic System (SS). Alkylated histamine based double action Saltans are lipophilic and can act transdermally.

A hypoglycemic and antihypertensive medicine is prepared from corn tassel, carrot and white gourd peel. Its advantages are widely available raw materials, high curative effect and no by-effect.